# RVMD Stock vs the S&P 500: Returns, Risk and Crash History

> Revolution Medicines, Inc., healthcare (market value $41.6 billion): how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Source: https://www.exent.ai/stocks/rvmd · Reviewed by David, Senior Analyst, Exent · Published Oct 29, 2026 · Updated Nov 15, 2026

**What changed since Nov 9, 2026:** 3 new ratings · analysts covering 28 → 30

## Key takeaways

- RVMD returned +550.1% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it beat the index.
- Its 5-year Sharpe ratio was 0.90 against 0.58 for the S&P 500.
- Its deepest crisis drawdown was −46.5% in the 2022 inflation bear market (S&P 500: −25.4%).
- Five‑year volatility was 61.8% and beta 1.43.
- 30 analysts rated it in the past year; 93% of their latest calls were Buy.
- RVMD beat earnings estimates in 2 of its last 12 reports; the stock moved 4.7% on average, up or down, around each report.

## Did RVMD beat the S&P 500?

Over the 5 years to Oct 30, 2026, Revolution Medicines, Inc. (RVMD) returned **+550.1%** including dividends, versus **+75.9%** for the S&P 500 (SPY). It beat the index by 474.2 percentage points, or +45.4% a year against +12.0%.

| Period | RVMD | S&P 500 | RVMD per year | S&P 500 per year | Result |
| --- | --- | --- | --- | --- | --- |
| 1 year | +225.1% | +12.0% | +225.1% | +12.0% | Beat |
| 3 years | +866.2% | +87.4% | +113.0% | +23.3% | Beat |
| 5 years | +550.1% | +75.9% | +45.4% | +12.0% | Beat |

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also [how to beat the S&P 500](https://www.exent.ai/beat-the-market).

## What Wall Street analysts say about RVMD

In the 12 months to 30 days ago, 30 analysts published 446 ratings on RVMD. Their latest calls were 93% Buy, 7% Hold and 0% Sell. 15 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $257.59 (range $179.00–$350.00), +61.2% from the last price. Remember that the average analyst’s target is hit only about half the time: [how accurate are price targets?](https://www.exent.ai/resources/are-analyst-price-targets-accurate)

| Top‑ranked analyst covering | Firm | Stars | Price‑target hit rate |
| --- | --- | --- | --- |
| [Faisal Khurshid](https://www.exent.ai/analysts/faisal-khurshid) | [Jefferies](https://www.exent.ai/firms/jefferies) | 5.0★ | 51.7% |
| [Tyler Van Buren](https://www.exent.ai/analysts/tyler-van-buren) | [TD Cowen](https://www.exent.ai/firms/td-cowen) | 5.0★ | 50.9% |
| [Ami Fadia](https://www.exent.ai/analysts/ami-fadia) | [Needham](https://www.exent.ai/firms/needham) | 5.0★ | 37.2% |
| Members only | Members only | 4.9★ | 40.4% |
| Members only | Members only | 4.9★ | 60.6% |

Other analysts covering RVMD: [Charles Zhu](https://www.exent.ai/analysts/charles-zhu) · [Laura Prendergast](https://www.exent.ai/analysts/laura-prendergast) · [Joseph Catanzaro](https://www.exent.ai/analysts/joseph-catanzaro) · [Leonid Timashev](https://www.exent.ai/analysts/leonid-timashev) · [Kelsey Goodwin](https://www.exent.ai/analysts/kelsey-goodwin) · [Sean Laaman](https://www.exent.ai/analysts/sean-laaman)

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on RVMD are, their live calls and the median target of only the top‑rated analysts are in [Exent Gems](https://www.exent.ai/radar).

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. [Unlock the top 50 analysts](https://www.exent.ai/radar).

## RVMD returns by year vs the S&P 500

RVMD beat the S&P 500 in 3 of the 5 full calendar years shown.

| Year | RVMD | S&P 500 | Difference |
| --- | --- | --- | --- |
| 2026 (to Oct 30, 2026) | +140.2% | +11.7% | +128.5% |
| 2025 | +82.1% | +17.7% | +64.4% |
| 2024 | +52.5% | +24.9% | +27.6% |
| 2023 | +20.4% | +26.2% | −5.8% |
| 2022 | −5.4% | −18.2% | +12.8% |
| 2021 | −36.4% | +28.7% | −65.1% |

## RVMD risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, RVMD had a Sharpe ratio of **0.90** against 0.58 for the S&P 500, so it earned more return per unit of risk than the index. Its annualized volatility was 52.6% and its beta 1.43: it tended to move about 1.4× as much as the market.

| Metric | RVMD | S&P 500 |
| --- | --- | --- |
| Annual return | +45.4% | +12.0% |
| Volatility (annualized) | 52.6% | 15.5% |
| Sharpe ratio | 0.90 | 0.58 |
| Sortino ratio | 1.70 | 0.91 |
| Max drawdown (month-end) | −42.3% | −23.9% |
| Beta to the S&P 500 | 1.43 | 1.00 |

[Sharpe](https://www.exent.ai/learn/sharpe-ratio) divides return above cash by total volatility; [Sortino](https://www.exent.ai/learn/sortino-ratio) counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

## How RVMD behaved in past crashes

RVMD’s deepest fall in the crises below was **−46.5%** in the 2022 inflation bear market, against −25.4% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

| Crisis | RVMD | S&P 500 | Loss on $100,000 |
| --- | --- | --- | --- |
| 2022 inflation bear market | −46.5% | −25.4% | −$46,490 |
| 2025 tariff selloff | −26.5% | −19.0% | −$26,480 |

| Window | RVMD max drawdown |
| --- | --- |
| Last 1 year | −25.0% |
| Last 3 years | −48.6% |
| Last 5 years | −58.2% |
| Last 10 years | −73.3% |

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the [crash test](https://www.exent.ai/tools/crash-test).

## What moves with RVMD, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, RVMD’s correlation with the S&P 500 was **0.42**, with the Nasdaq‑100 0.42, with long Treasuries (TLT) 0.31 and with gold (GLD) 0.14.

Adding a 5% RVMD position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 16.0%.

| Least correlated large caps | Correlation | Most correlated large caps | Correlation |
| --- | --- | --- | --- |
| [COP](https://www.exent.ai/stocks/cop) | −0.18 | [PWR](https://www.exent.ai/stocks/pwr) | 0.60 |
| [T](https://www.exent.ai/stocks/t) | −0.16 | [CAT](https://www.exent.ai/stocks/cat) | 0.52 |
| [XOM](https://www.exent.ai/stocks/xom) | −0.09 | [GOOGL](https://www.exent.ai/stocks/googl) | 0.48 |
| [MPC](https://www.exent.ai/stocks/mpc) | −0.09 | [WDC](https://www.exent.ai/stocks/wdc) | 0.47 |
| [TMUS](https://www.exent.ai/stocks/tmus) | −0.08 | [VRT](https://www.exent.ai/stocks/vrt) | 0.46 |

Holdings that are highly correlated behave like one position in a selloff. See [how to find hidden overlap](https://www.exent.ai/resources/is-my-portfolio-diversified).

## Latest RVMD upgrades, downgrades and price‑target changes

| Date | Rating and target | Analyst |
| --- | --- | --- |
| Nov 13 | Target cut Buy Target $247, was $272 | [Sean Laaman](https://www.exent.ai/analysts/sean-laaman) Morgan Stanley |
| Nov 6 | Target raised Buy Target $350, was $280 | [Robert Burns](https://www.exent.ai/analysts/robert-burns) H.C. Wainwright |
| Nov 5 | Target raised Buy Target $270, was $250 | [Tyler Van Buren](https://www.exent.ai/analysts/tyler-van-buren) TD Cowen |
| Nov 5 | Target raised Buy Target $222, was $210 | [Kelsey Goodwin](https://www.exent.ai/analysts/kelsey-goodwin) Piper Sandler |
| Nov 5 | Target raised Buy Target $321, was $260 | [Leonid Timashev](https://www.exent.ai/analysts/leonid-timashev) RBC Capital |
| Nov 5 | Target raised Buy Target $272, was $255 | [Sean Laaman](https://www.exent.ai/analysts/sean-laaman) Morgan Stanley |
| Oct 15 | New coverage Buy Target $226 | Sharon Zackfia William Blair |
| Oct 15 | New coverage Buy Target $226 | Alethia Young William Blair |
| Oct 8 | Target raised Buy Target $259, was $251 | [Leonid Timashev](https://www.exent.ai/analysts/leonid-timashev) RBC Capital |
| Sep 28 | New coverage Buy Target $318 | Leah R. Cann Brookline Capital Markets |
| Sep 24 | New coverage Buy Target $267 | Andrea Newkirk Goldman Sachs |
| Sep 21 | Target raised Buy Target $265, was $225 | Alec Stranahan Bank of America Securities |

Named analysts’ rating and price‑target changes on RVMD in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in [Exent Gems](https://www.exent.ai/radar). [See all of the latest analyst upgrades and downgrades](https://www.exent.ai/analysts/upgrades).

## Do analysts get RVMD right?

Of the 228 analyst price targets on RVMD set from 2019 until a year ago, **77.2%** were reached within 12 months (data to Oct 20, 2026), 8.6 points above the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 108 days. The median target sat 40.9% above the share price on the day it was set.

Where analysts said RVMD would be by now: a year ago, 10 analysts had a price target on RVMD, and the median of their latest targets was **$82.00**. On Oct 20, 2026 RVMD closed at $196.55, 139.7% above it.

- **77.2%** of targets reached within 12 months

- **108 days** median time to reach a target

- **+139.7%** price now vs the median target set a year ago

| After | Calls | Move on the call | 3 months vs S&P 500 |
| --- | --- | --- | --- |
| Upgrades of RVMD | 3 | +4.4% | −2.7% |
| Upgrades, all stocks | 11,514 | +2.5% | +3.4% |

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on RVMD through Sep 15, 2026; analysts are not named here. [Do analyst upgrades move stocks?](https://www.exent.ai/resources/do-analyst-upgrades-move-stocks)

## How RVMD moves after earnings

RVMD beat the consensus earnings‑per‑share estimate in **2 of its last 12** quarterly reports, through the one on Aug 5, 2026, and the revenue estimate in 1 of 1. From the close before each report to the close after it, the stock moved 4.7% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 5 of the 12 reports. In 2 of the 2 beats the stock still fell.

- **2/12** earnings beats

- **±4.7%** average move per report

- **5/12** reports followed by a rise

| Report | EPS vs estimate | Revenue vs estimate | Stock move |
| --- | --- | --- | --- |
| Aug 5, 2026 | −$3.06 vs −$2.04 | — | +2.2% |
| May 6, 2026 | −$2.29 vs −$1.84 | — | −3.2% |
| Feb 25, 2026 | −$1.86 vs −$1.58 | — | −2.6% |
| Nov 5, 2025 | −$1.61 vs −$1.42 | — | +4.8% |
| Aug 6, 2025 | −$1.31 vs −$1.14 | — | −9.0% |
| May 7, 2025 | −$1.13 vs −$1.12 | — | +11.9% |
| Feb 26, 2025 | −$1.12 vs −$1.01 | — | −5.5% |
| Nov 6, 2024 | −$0.94 vs −$0.89 | — | +4.1% |

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. [How stocks move after earnings](https://www.exent.ai/resources/how-stocks-move-after-earnings)

## Where RVMD’s revenue comes from

In fiscal 2022, RVMD’s largest segment was Collaboration Revenue Member, with 100.0% of $35.4 million revenue (+20.4% on the year before).

From RVMD’s annual filings; segment growth compares fiscal 2022 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. [Which S&P 500 companies depend most on China?](https://www.exent.ai/resources/sp-500-china-revenue-exposure)

## Are RVMD insiders buying or selling?

In the 12 months to Oct 20, 2026, RVMD insiders made **no open‑market purchases** and **158 sales** worth $100.5 million, according to SEC Form 4 filings. The last open‑market purchase on record was on Dec 5, 2024.

After the 17 insider purchases of $10,000 or more since 2012, RVMD beat the S&P 500 by an average of 14.5 percentage points over the next 12 months; 65% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

| Date | Insider | Role | Value |
| --- | --- | --- | --- |
| Dec 5, 2024 | Schroeder Thilo | Director | $25.0 million |
| Mar 10, 2023 | Schroeder Thilo | Director | $129,270 |
| Mar 7, 2023 | Schroeder Thilo | Director | $5.1 million |
| Jul 22, 2022 | Schroeder Thilo | Director | $5.0 million |
| Jul 22, 2022 | Kim Lorence H. | Director | $1.0 million |

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. [Do insider buys beat the market?](https://www.exent.ai/resources/do-insider-buys-beat-the-market)

## How much of RVMD is sold short?

As of the Sep 30, 2026 settlement date, **6.18%** of RVMD’s float was sold short: 11.9 million shares, or 4.7 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 10.03%. The median across the 997 US stocks Exent tracks was 4.77%, so RVMD is more heavily shorted than most.

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. [The most shorted stocks](https://www.exent.ai/resources/most-shorted-stocks)

## How many institutions own RVMD?

At the end of Q2 2026 (Jun 30, 2026), **738 institutions** reported holding RVMD in 13F filings, up 179 from the quarter before and up from 324 a year earlier. Their reported holdings add up to 102.4% of RVMD’s shares. In the quarter 490 institutions added to their positions and 155 cut them.

- **738** 13F holders

- **248** new positions

- **65** positions closed

- **102.4%** of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. [Which stocks institutions are buying and selling](https://www.exent.ai/resources/institutional-ownership-13f-changes)

## Is RVMD diluting shareholders?

RVMD’s diluted share count **rose 185.5%** over the five fiscal years to fiscal 2025 and rose 13.3% in fiscal 2025 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $118.4 million in fiscal 2025. RVMD did not buy back shares in fiscal 2025.

- **+13.3%** share count, 1 year

- **+185.5%** share count, 5 years

- **0.00%** buyback yield

Weighted‑average diluted shares from RVMD’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. [Stock dilution and stock‑based compensation, explained](https://www.exent.ai/resources/stock-dilution-and-stock-based-compensation)

## RVMD financial health scores

In Exent’s Oct 20, 2026 snapshot, RVMD’s Altman Z‑score was **12.07**, in the safe zone (where 465 of the 794 non‑financial US stocks Exent tracks sit). Its Piotroski F‑score was **1 out of 9**; 100% of scored stocks reach 1 or more.

- **12.07** Altman Z‑score: safe zone

- **1/9** Piotroski F‑score

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. [Which stocks have the highest bankruptcy risk?](https://www.exent.ai/resources/altman-z-score-bankruptcy-risk-stocks)

## Which ETFs hold RVMD?

As of Oct 20, 2026, **28** of the 304 ETFs Exent tracks held RVMD. Its largest weight is in XBI (State Street SPDR S&P Biotech ETF), at 1.34% of the fund.

| ETF | Fund | Weight of RVMD |
| --- | --- | --- |
| XBI | State Street SPDR S&P Biotech ETF | 1.34% |
| [VBK](https://www.exent.ai/etfs/vbk) | Vanguard Small-Cap Growth Index Fund ETF Shares | 1.19% |
| FXH | First Trust Health Care AlphaDEX Fund | 1.17% |
| [IWP](https://www.exent.ai/etfs/iwp) | iShares Russell Mid-Cap Growth ETF | 1.04% |
| [VB](https://www.exent.ai/etfs/vb) | Vanguard Small-Cap Index Fund ETF Shares | 0.53% |
| [VXF](https://www.exent.ai/etfs/vxf) | Vanguard Extended Market Index Fund ETF Shares | 0.50% |
| [VHT](https://www.exent.ai/etfs/vht) | Vanguard Health Care Index Fund ETF Shares | 0.49% |
| [MTUM](https://www.exent.ai/etfs/mtum) | iShares MSCI USA Momentum Factor ETF | 0.30% |

Owning several of these funds stacks the same position. [How much do VOO, QQQ and VTI overlap?](https://www.exent.ai/resources/etf-overlap-voo-qqq-vti)

## The right benchmark for RVMD

Exent matches every holding to the index with the most similar risk. For RVMD that is **SPY** (the S&P 500). Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read [why the S&P 500 is the wrong benchmark for most portfolios](https://www.exent.ai/resources/why-the-sp-500-is-the-wrong-benchmark).

## Other healthcare stocks

| Ticker | Name | 5‑year return | Volatility (5y) |
| --- | --- | --- | --- |
| [LLY](https://www.exent.ai/stocks/lly) | Eli Lilly and Company | +482.3% | 32.6% |
| [JNJ](https://www.exent.ai/stocks/jnj) | Johnson & Johnson | +92.9% | 16.8% |
| [ABBV](https://www.exent.ai/stocks/abbv) | AbbVie Inc. | +207.1% | 23.5% |
| [BIIB](https://www.exent.ai/stocks/biib) | Biogen Inc. | −4.9% | 33.3% |
| [IQV](https://www.exent.ai/stocks/iqv) | IQVIA Holdings Inc. | +2.3% | 33.2% |
| [GEHC](https://www.exent.ai/stocks/gehc) | GE HealthCare Technologies Inc. | — | — |
| [WAT](https://www.exent.ai/stocks/wat) | Waters Corporation | +25.9% | 33.4% |
| [ILMN](https://www.exent.ai/stocks/ilmn) | Illumina, Inc. | −41.5% | 45.2% |

## Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: [Exent methodology](https://www.exent.ai/methodology).

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

## Check RVMD with Exent Gems

Wall Street’s average RVMD price target is 61.2% above the latest share price. See what the best‑ranked analysts on RVMD say now in Exent Gems.

1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
2. Gems shows who the top‑ranked analysts covering RVMD are, their live calls and the median target of only the top‑rated analysts.
3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product: [Exent Gems](https://www.exent.ai/radar)

Also: [Stress‑test your portfolio with RVMD](https://www.exent.ai/portfolio)

## Frequently asked questions

### Did RVMD beat the S&P 500 over the last 5 years?

Yes. RVMD returned +550.1% (+45.4% a year) over the 5 years to Oct 30, 2026, versus +75.9% (+12.0% a year) for the S&P 500, including dividends.

### Is RVMD in the S&P 500?

No. As of Oct 20, 2026, RVMD (Revolution Medicines, Inc.) is not one of the 503 stocks in the S&P 500.

### Is RVMD in the Nasdaq-100?

No. As of Oct 20, 2026, RVMD (Revolution Medicines, Inc.) is not one of the 101 stocks in the Nasdaq-100.

### How much did RVMD fall in the 2022 bear market?

RVMD fell −46.5% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

### What is RVMD’s Sharpe ratio?

Over the 5 years to Oct 30, 2026, RVMD’s Sharpe ratio was 0.90 and its Sortino ratio 1.70, versus 0.58 and 0.91 for the S&P 500.

### Is RVMD a volatile stock?

RVMD’s 5‑year annualized volatility was 61.8%, higher than the S&P 500’s 17.0%, with a beta of 1.43.

### What is least correlated with RVMD?

Among large US stocks, the lowest correlations with RVMD over the last 60 months were COP (−0.18), T (−0.16), XOM (−0.09). Its correlation with long Treasuries (TLT) was 0.31 and with gold (GLD) 0.14.

### Does RVMD usually beat earnings estimates?

RVMD beat the consensus earnings-per-share estimate in 2 of its last 12 quarterly reports through Aug 5, 2026, and the revenue estimate in 1 of 1. The stock moved 4.7% on average, up or down, from the close before each report to the close after it.

### What is RVMD’s short interest?

As of the Sep 30, 2026 settlement date, 6.18% of RVMD’s float was sold short (11.9 million shares, 4.7 days to cover), according to FINRA short-interest reports. A year earlier it was 10.03%.

### Is RVMD diluting shareholders?

Yes. RVMD’s diluted share count rose 185.5% over the five fiscal years to fiscal 2025 and rose 13.3% in the latest year.

---

Educational content, not investment advice. Past performance does not guarantee future results.
